Contact
searchSearch
HMP Global

Advertisement

Advertisement

ADVERTISEMENT

Meet Our Team

 

Editorial Staff

Senior Managing Editor: Meagan Thistle
mthistle@hmpglobal.com

Associate Editor: Brionna Mendoza
bmendoza@hmpglobal.com

Associate Editor: Evi Arthur
earthur@hmpglobal.com

Business Staff

Sales Director: Mark Kennedy
mkennedy@hmpglobal.com

National Accounts, Psychiatry & Behavioral Health Learning Network: pbhlnsales@hmpglobal.com

 

Advertisement

Advertisement

Advertisement

Popular Now

News
Distinct Gene Expression Signature Identified in Group of Patients With MDD
06/20/2022
Jolynn Tumolo
Patients with MDD who died by suicide had a gene expression signature distinct from other patients with MDD that included genes involved in stress response and polyamine metabolism, immune response, and telomere maintenance.
Patients with MDD who died by suicide had a gene expression signature distinct from other patients with MDD that included genes involved in stress response and polyamine metabolism, immune response, and telomere maintenance.
Patients with MDD who died by...
06/20/2022
Psych Congress Network
Jill HF
Greater Suicide Prevention Efforts Needed in Clinical Practice, Experts Say
09/02/2022
Jill Harkavy-Friedman, PhD, shares her hopes for this year's annual Suicide Prevention Week and clinical pearls.
Jill Harkavy-Friedman, PhD, shares her hopes for this year's annual Suicide Prevention Week and clinical pearls.
Jill Harkavy-Friedman, PhD,...
09/02/2022
Psych Congress Network
News
Psychoactive Drug Schedule Classification Out of Sync With Psychiatrist Views
11/22/2022
Jolynn Tumolo
Nonprescribed use of methamphetamine and alprazolam "more concerning" and less acceptable than nonprescribed use of psilocybin and ketamine.
Nonprescribed use of methamphetamine and alprazolam "more concerning" and less acceptable than nonprescribed use of psilocybin and ketamine.
Nonprescribed use of...
11/22/2022
Psych Congress Network
News
FDA Approves Bi-Weekly Extended-Release Risperidone for Schizophrenia and Bipolar I
01/16/2023
Meagan Thistle
US FDA approved Rykindo® (risperidone), an extended-release injectable suspension to treat schizophrenia and bipolar I in adult patients.
US FDA approved Rykindo® (risperidone), an extended-release injectable suspension to treat schizophrenia and bipolar I in adult patients.
US FDA approved Rykindo®...
01/16/2023
Psych Congress Network
News
New APA Eating Disorder Guidelines Advise Patient-Centered Care
04/24/2023
Evi Arthur
This is the first new protocol the board has released since 2006
This is the first new protocol the board has released since 2006
This is the first new protocol...
04/24/2023
Psych Congress Network

Advertisement

Advertisement

Advertisement

Sign Up

Psychiatry & Behavioral Health Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement